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Abstract
Our previous studies have demonstrated the critical roles of calcium-stimulated adenylyl cyclase 1 (AC1) in the central
nervous system in chronic pain. In the present study, we examined the analgesic effects of NB001, a selective inhibitor
of AC1, on animal models of ankle joint arthritis and knee joint arthritis induced by complete Freund’s adjuvant
injection. NB001 treatment had no effect on joint edema, stiffness, and joint destruction. Furthermore, the
treatment failed to attenuate the disease progression of arthritis. However, NB001 treatment (3 mg/kg)
significantly weakened joint pain-related behavior in the mouse models of ankle joint arthritis and knee joint
arthritis. Results indicated that NB001 exhibited an analgesic effect on the animal models of arthritis but was
not caused by anti-inflammatory activities.
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Background
Arthritis is the most common musculoskeletal disease
and is characterized by joint inflammation, stiffness,
pain, and cartilage damage [1]. Among these symptoms,
arthralgia negatively influences the articular function
and quality of life of patients. Chronic arthralgia not
only leads to mobility disorders and physical disability
but also causes a substantial amount of emotional and eco-
nomic stress [2, 3]. However, the mechanism underlying
arthritic joint pain is still poorly understood. Non-steroidal
anti-inflammatory drugs and opioids have been widely
used as therapies in the clinical treatment of arthritic joint
pain for decades [4, 5]. However, the long-term use of both
treatments exhibit non-negligible adverse effects.
Arthritic joint pain often occurs when the affected
joint is moved and/or loaded but can also occur at rest
[6, 7]. Spontaneous pain (joint pain at rest), movement-
evoked pain, thermal hyperalgesia, mechanical allodynia,
and joint hyperalgesia are the main features of arthritic
pain [8–10]. Arthritic joint pain results in part from
inflammation-induced articular nerve sensation and the
activation of peripheral and central neuronal mechanisms
[11]. Upon development of inflammation, numerous silent
joint nociceptors develop sensitivity for stimulation; this
recruitment of fibers significantly increases input into the
spinal cord [12, 13]. Ascending spinal nociceptive neurons
show gradually increasing response to the innocuous and
noxious stimulation exerted on inflamed joints. The gen-
eration and maintenance of central sensitization are medi-
ated by various transmitter systems in the spinal cord and
related brain regions [14]. As a key transmitter in the ner-
vous system, glutamate, including its receptors, is essential
for joint nociception; furthermore, NMDA receptor acti-
vation is critically involved in central sensitization and
joint inflammatory hypersensitivity [15, 16].
Cyclic adenosine monophosphate (cAMP) is a key intra-
cellular second messenger involved in many physiological
functions, such as nociception perception, learning and
memory, emotional fear, and addiction [17–19]. As an
enzyme that catalyzes ATP to cAMP, calcium-stimulated
adenylyl cyclase subtype 1 (AC1) is highly expressed in
neurons and critically involved in pain-related long-term
potentiation (LTP) in both the spinal cord dorsal horn [20]
and the anterior cingulate cortex (ACC) [21]. AC1 signifi-
cantly contributes to behavioral sensitization and spinal
facilitation in animal models of pain as a downstream of
glutamate NMDA receptors [22]. AC1 knockout mice have
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been known to show hypalgesia to inflammatory pain,
muscle pain, and neuropathic pain without evident alter-
ations in physiological functions [23–25]. NB001, a select-
ive inhibitor of AC1, exhibits analgesic effects on several
animal models of chronic pain, including neuropathic pain,
inflammation pain, and irritable bowel syndrome-induced
visceral pain [23, 26]. Furthermore, no obvious side effects
have been observed when NB001 is applied in animal
models [23].
The analgesic effects of NB001 on arthritic joint pain
have not been investigated. In this study, we aimed to
examine the analgesic effect of NB001 on the (i) ankle
joint pain induced by injecting complete Freund’s adju-
vant (CFA) into the hind metatarsal footpad, as well as
on the (ii) knee joint pain caused by CFA administration
into the knee joint cavity. The anti-inflammatory effects
of NB001 on CFA-induced arthritis, including edema,
stiffness, and joint damage were also measured.
Results
NB001 exerted no effect on CFA-induced joint
inflammation
Experimental procedure of two arthritic pain models was
sown in the Fig. 1. To assess joint inflammation quantita-
tively, the diameters of the ankle joint or knee joint were
measured by using a vernier caliper. Figure 2a shows inev-
itable ankle joint edema 3 days after the mice received
CFA injection in the hind metatarsal footpad. The edema
lasted at least to the end of the experiment (day 18).
NB001 administration (3 mg/kg, from day 14 to day 18)
showed no obvious effects on ankle edema. In the knee
joint model, the joint thickness of the knee increased grad-
ually after the initial CFA injection. Similarly, NB001 treat-
ment cannot alleviate knee joint swelling (Fig. 2b). Results
showed that NB001 may exhibit no effects on CFA-
induced joint inflammation.
Effect of NB001 on joint pain-related behaviors
Flinching behavior indicates spontaneous pain, which
mimics the clinical condition of arthritic patients with
joint pain at rest. Subsequent to CFA injection into the
metatarsal footpad, the number of hindpaw flinches sig-
nificantly increased, peaked on day 7, and then decreased
gradually but remained apparently higher than that of
control mice (Fig. 3a1). For knee joint arthritic models,
the number of flinches markedly increased and peaked on
day 17 compared with the control (Fig. 3b1). NB001 treat-
ment (3 mg/kg) sharply decreased the number of flinches
in both ankle and knee arthritic animal models. On day
28, the number of flinches of the knee joint arthritic mice
treated with NB001 became comparable with that of nor-
mal mice (Fig. 3b1).
Limb use, an indicator of stimulus-evoked pain, was
measured (with scores ranging from five to zero) to further
evaluate the effects of NB001. The mean score of limb use
rapidly decreased after the mice received CFA injection
either into the hind metatarsal footpad (Fig. 3a2) or the
knee joint cavity (Fig. 3b2). NB001 administration for 5
Fig. 1 Schematic experimental procedure of two arthritic pain models. On the day before CFA injection (day 0), basal behavioral tests and joint diameters
were detected. Then, mice were injected with CFA in hind metatarsal footpad (upper paradigm) or into intra-articular space of knee (lower paradigm) to
induce arthritic pain of ankle and knee respectively. For the knee arthritis model, the mice received another three intra-articular CFA injection on day 7, 14,
21. For the control mice, the same volume of saline was injected at the same time points with that of CFA injection. Behavioral tests were performed on
day 3, 7, 14 16, 18 for ankle arthritic pain model and day 4, 11, 17, 24, 26, 28 for knee arthritic pain model. NB001 (3 mg/kg, i.p.) or saline was injected to
mice once daily from day 14 to day 18 in ankle arthritis model and day 24 to day 28 in knee arthritis model. At the first day of treatment (day 14 and day
24 respectively), NB001 or saline was administrated after the behavioral tests. On day 15, 17 in ankle arthritis model and day 25, 27 in knee arthritis model,
the mice were just received NB001 or saline administration and no behavioral tests were performed. The related behavioral tests were conducted within
2.5 h on day 16, 18 and day 26, 28 in two models respectively following NB001 or saline treatment
Tian et al. Molecular Brain  (2015) 8:60 Page 2 of 10
days significantly increased the limb use score in mice with
ankle and knee joint arthritis.
Subsequently, limb use during forced ambulation was
detected by using a rotarod test with a similar scale.
Figure 3a3, b3 show a remarkable decrease in the aver-
age score of forced limb use in both types of arthritic
models. NB001 administration obviously relieved pain,
as reflected by the rotarod test in two animal models.
These combined results revealed persistent joint pain in
CFA-induced ankle arthritis or knee joint arthritis. Fur-
thermore, NB001 showed evident analgesic effects on
adjuvant-induced joint pain.
NB001 increased the mechanical threshold
To further examine the analgesic effect of NB001 on the
types of pain behavior associated with arthritis, mechan-
ical allodynia was detected in both animal models. The
mechanical paw withdrawal threshold (MPWT) in ipsi-
lateral hindpaw decreased immediately and significantly
in mice injected with CFA into the metatarsal footpad
(Fig. 4a). NB001 administration (3 mg/kg from day 14)
markedly increased the mechanical threshold on days 16
and 18 compared with saline treatment (Fig. 4a). Knee
intra-articular CFA injection gradually decreased MPWT
and NB001 obviously attenuated mechanical allodynia
(Fig. 4b). No obvious difference was observed in MPWT in
contralateral paws among groups in both types of animal
models (Fig. 4a, b) within the entire experimental period.
NB001 increased the thermal threshold
On the last day of the experiment (day 18), the thermal
paw withdrawal latency of mouse models of ankle joint
arthritis were measured. NB001 treatment (3 mg/kg)
showed apparently higher thermal paw withdraw latency
than saline treatment in CFA-injected mice (F(2,21) = 26.555,
p = 0.000, Dunnett’s test; Fig. 5a). Furthermore, the thermal
latency in contralateral hindpaw was comparable among
the three groups (F(2,21) = 0.275, p = 0.762, LSD test).
Effect of NB001 on joint hyperalgesia
Joint hyperalgesia was detected by recording the num-
bers of mice vocalization when bending and extension
were applied to the joint. Figure. 5b, c show extremely
low means for vocalization in the control mice. The
numbers of vocalization in both mouse models of ipsilat-
eral joint pain increased sharply in both mouse models
(F(2,21) = 123.141, p = 0.000, Dunnett’s test; Fig. 5b and
F(2,21) = 171.64, p = 0.000, LSD test; Fig. 5c). NB001 treat-
ment (3 mg/kg) significantly decreased the number of
vocalizations in both mouse models of ankle joint pain
and knee joint pain. The numbers of vocalization among
the groups in both models of contralateral joint pain
were similar (F(2,21) = 0.191, p = 0.828, LSD test; Fig. 5b
and F(2,21) = 0.653, p = 0.531, LSD test; Fig. 5c).
NB001 exerted no effect on joint stiffness
Joint stiffness was assessed by the bending and extension
test and was used as an indicator in progressive arthritis
development in adjuvant arthritis models [27]. No restric-
tion was set on the full-range movement of joints in any
mice on day 0, and the joints of the control mice showed
no restriction throughout the whole experimental period
(Fig. 6). The joint stiffness score increased sharply and
remained at an increased level in the ipsilateral ankle fol-
lowing CFA injection (Fig. 6a). This score increased pro-
gressively in the ipsilateral knee following CFA injection
(Fig. 6b). NB001 treatment (3 mg/kg) showed no evident
influence on ankle or knee joint stiffness.
NB001 showed no improvement on arthritis-induced
joint damage
The histological evaluation of ankle and knee joint tis-
sues was performed on day 18 and 28, respectively
(Fig. 7). The histological architecture of the ankle joint
showed abnormality in mice after the induction of ankle
joint arthritis, as shown by inflammatory cell infiltration,
Fig. 2 The effect of NB001 on joints edema induced by CFA injection. a Ankle diameter reached the maximum on day 3 following CFA injection
and then it remained at a higher level compared with control. NB001 treatment (3 mg/kg, i.p.) did not attenuate the ankle edema. b There was a
significant increase of knee diameter after intra-articular CFA injection. NB001 administration did not alleviate the inflammation. n = 8 mice in each
group. *p < 0.05, **p < 0.01 compared to the control group
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synovial hyperplasia, and degeneration of the articular
cartilage (Fig. 7b). Intra-articular CFA injection (4
times) caused abnormalities in knee joint structures,
including pronounced synovial hyperplasia and in-
flammation, displacement of the meniscus, thickening
of the joint capsule, and intra-articular fibrin accumu-
lation (Fig. 6e). NB001 administration (3 mg/kg) for
5 days failed to evidently attenuate CFA-induced joint
damages in both types of arthritic models (Fig.6c, f ).
These results demonstrated again that NB001 exerted
no anti-inflammatory effects and failed to alleviate
inflammation-induced joint damage.
Discussion
Arthritis can affect people at any age, and its prevalence
increases with age. Chronic joint pain, the most debili-
tating symptom of arthritis, prompts patients to seek
medical help. However, few effective therapies exert no
undesirable side effects [28]. Therefore, new therapies
for alleviating arthritic joint pain need to be developed.
AC1 acts as a key molecule for triggering chronic-
pain-related central plasticity. AC1 is considered indis-
pensable for the induction of both spinal and ACC LTP,
which is one of the possible cellular mechanisms under-
lying chronic pain [21]. Genetically, the knockout of
Fig. 3 NB001 alleviates arthritic pain behaviors. a Data from the ankle joint arthritic model. A1: The number of spontaneous flinches increased significantly
and reached a peak on day 7 following CFA injection and maintained at a higher level as compared with the control. In addition, the score of normal limb
use (A2) and forced ambulation (rotarod) (A3) declined significantly after the CFA injection. b Data from the knee joint arthritic model. B1: Mice exhibited a
gradually increased spontaneous flinches. The score of normal limb use (B2) and forced ambulation (rotarod) (B3) declined significantly after the CFA
injection. NB001 treatment (3 mg/kg, i.p.) significantly attenuated pain-related behaviors in two types of model (a and b). n= 8 in each group. *p< 0.05,
**p< 0.01 compared to the control group; #p< 0.05, ##p< 0.01 compared to the CFA group
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AC1 reduced mice behavioral response to chronic pain
caused by peripheral inflammation or nerve injury with
the impaired LTP induction. Nociceptive responses were
also remarkably inhibited in the persistent muscle pain
model of AC1 knockout mice [25]. On the basis of these
results, inhibiting AC1 activity may be a novel mechan-
ism for chronic pain treatment [29]. As the first selective
inhibitor of AC1, the analgesic effect of NB001 has been
investigated in our previous studies. NB001 exhibited
significant analgesic effects in the animal models of neuro-
pathic pain, which was comparable to those produced by
gabapentin [23]. Behavioral allodynia was also inhibited by
NB001 in the animal models of inflammatory pain, with
higher doses exerting greater inhibition [20].
Alleviating the joint pain of arthritic patients can in-
crease functional recovery and improve quality of life. In
this study, we investigated the analgesic role of NB001
on CFA-induced arthritic pain in two arthritis models.
We demonstrated that NB001 produced antinociceptive
effects in both mouse models of ankle joint pain and
knee joint pain. However, NB001 failed to exhibit anti-
inflammatory effects, as indicated by no attenuation of
the related abnormal changes induced by inflammation.
Nociceptive articular pain originates locally in the joint
at the site of inflammation or injury. CFA has been widely
used to induce arthritic pain because of its ability to cause
chronic inflammation in rodents [30] and produce a
disease-like state that most closely resembles human arth-
ritis [31]. CFA injection leads to T-lymphocytes and
macrophage infiltration, which progress with joint swell-
ing and synovial hypertrophy accompanied by significant
reduction in joint cavity volume and severe osteolytic
lesion [32, 33]. In our experiment, we first examined the
effect of NB001 on CFA-induced joint inflammation.
NB001 showed no obvious effects on joint edema caused
by CFA injection. Joint stiffness results from long-term
inflammation and indicates disease development together
with abnormal mobility behavior in arthritic models [27].
Patients with arthritis also showed increased joint stiffness
and decreased maximal amplitude of flexion and exten-
sion [34]. In the current study, mice exhibited apparent
ankle or knee joint stiffness indicated by notable restric-
tion of full-range joint movement following metatarsal or
knee intra-articular CFA injection. Treatment with NB001
for 5 days exhibited no influence on the joint stiffness
score. The effects of NB001 on joint swelling and stiffness
implied that NB001 had no anti-inflammatory effect and
could not prevent the progressive development of arthritis.
This presumption was further demonstrated by the immu-
nohistochemical analysis of a joint slice. CFA injection
Fig. 4 NB001 attenuates mechanical allodynia. a Mechanical threshold in the ipsilateral hindpaws decreased in the mice following CFA injection
into metatarsal footpad, but had no alteration in the contralateral paws. NB001 administration attenuated the mechanical allodynia in the ipsilateral
hindpaws. b The mechanical allodynia occurred gradually following knee intra-articular CFA injection and the threshold decreased obviously from day
17 after initial CFA injection (three days after the third CFA injection), but had no alteration in the contralateral paws. NB001 administration attenuated
the mechanical allodynia in the ipsilateral hindpaws. n = 8 mice in each group. *p < 0.05, **p < 0.01 compared to the control group; #p < 0.05, ##p < 0.01
compared to the CFA group
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caused abnormal changes in both ankle joint and knee joint
as indicated by synovial hypertrophy, inflammatory cell in-
filtration, degeneration of the articular cartilage, and thick-
ening of the joint capsule. However, NB001 cannot
improve inflammation-induced joint destruction.
For arthritis, the analgesic effect must be distinguished
from an anti-inflammatory effect because analgesics
alleviate pain but may not attenuate the progressive
development of the disease [35, 36]. The analgesic ef-
fects of NB001 occurred in two types of CFA-induced
arthritic pain model. Spontaneous pain (joint pain at
rest) is an important behavioral symptom of arthritic
joint pain, and the number of hindpaw flinches was re-
corded as the measure of spontaneous nociceptive behav-
ior [6, 37]. CFA injections induced obvious spontaneous
pain, as indicated by the increase in the number of hind-
paw flinches. NB001 markedly inhibited spontaneous pain
in our experiment. Furthermore, stimulus-evoked pain be-
havior was also examined to measure arthritic pain be-
cause it mimics the clinical condition of arthritic patients
when the joint was moved [37]. Limb use scores during
spontaneous movement and forced ambulation (rotarod)
were used as the indexes of stimulus-evoked pain-related
behavior according to previous research [38, 39]. NB001
administration markedly increased limb use scores in both
mouse models of ankle and knee joint arthritis. These re-
sults showed that NB001 treatment inhibited spontaneous
movement and evoked pain in adjuvant-induced arthritis.
Thermal hyperalgesia, mechanical allodynia, and joint
hyperalgesia are the main secondary characteristics of arth-
ritic pain [40, 41]. Under the condition of chronic arthritic
pain, the threshold for nociceptor activation is lowered and
the response to mechanical or thermal stimuli is amplified
[42]. In our study, the mice showed significant and quick
mechanical allodynia, thermal hypersensitivity, and joint
hyperalgesia following CFA-induced ankle arthritis. How-
ever, knee intra-articular CFA injection led to a progressive
reduction in mechanical threshold, and the mice exhibited
apparent mechanical allodynia on day 17 after the initial
CFA injection (3 days after the third CFA injection). These
effects may be attributed to the fact that single knee joint
intra-articular CFA injection could not adequately cause
hindpaw mechanical hypersensitivity. NB001 treatment ex-
hibited pronounced attenuation of behavioral sensitization,
thus validating its analgesic effects on arthritic pain.
In conclusion, the results from our current study re-
vealed that NB001 exerted analgesic effects on arthritic
joint pain. Antinociception seemed unlikely to be associ-
ated with the anti-inflammatory effect because NB001
exhibited no anti-inflammatory action, as indicated by
the lack of attenuation of joint edema, stiffness, and joint
structural destruction caused by CFA. Combined with
the results of previous studies with NB001, NB001 can
be potentially used as a new analgesic.
Methods
Animals
All experiments were performed with adult male C57/BL6
mice aged from 8 to 10 weeks. Animals were housed under
standard laboratory conditions (12 h light/12 h dark,
temperature 22–26 °C, humidity 55–60 %) with food and
water provided ad libitum. Animals were allowed to
Fig. 5 Effects of NB001 on thermal and joint hyperalgesia. Thermal
hyperalgesia was examined on the last experimental day for ankle
arthritis mice. a CFA caused thermal hyperalgesia in the ipsilateral
hindpaw but not the contralateral hindpaw. NB001 administration
(3 mg/kg, i.p.) significantly inhibit thermal hyperalgesia. b Joint
hyperalgesia was assessed by the joint flexion test on the last
experimental day and expressed as the numbers of vocalization
caused by bending and extension of the joint (five times in each
direction). The mice exhibited evident ankle joint hyperalgesia
following CFA injection in the ipsilateral joint. c The mice exhibited
markedly knee joint hyperalgesia following CFA injection in the
ipsilateral joint. NB001 significantly (3 mg/kg, i.p.) attenuated both
ankle (b) and knee joint hyperalgesia (c) indicted by reduction of
vocalized numbers in joint flexion tests. n = 8 in each group.
*p < 0.05, **p < 0.01 compared to the control group; ##p < 0.01
compared to the CFA group
Tian et al. Molecular Brain  (2015) 8:60 Page 6 of 10
Fig. 7 Histological staining of ankle and knee joints. The representative sections of ankle joint from control mice (a) and CFA-injection mice
(b). CFA injection induced inflammatory cell infiltration, synovium hyperplasia, degeneration of the articular cartilage of the ankle joint. c NB001 treatment
(3 mg/kg, i.p.) did not attenuate CFA-induced ankle joint structural destruction. The representative sections of knee joint from control mice (d) and
CFA-injection mice (e). Four times knee intra-articular CFA injection induced abnormal structural changes of the knee joint, including bone, synovium,
and meniscus. f NB001 treatment (3 mg/kg, i.p.) did not attenuate CFA-induced knee joint structural destruction
Fig. 6 No effects of NB001 on CFA-induced joint stiffness. Joint stiffness was an indication of progressive disease development of arthritis. It was
reflected by restriction of full range of joint movement. There was obvious restriction on the full-range joint movement in ipsilateral ankle (a) or knee
(b) indicted by significant increase of joint stiffness scores. NB001 (3 mg/kg, i.p.) had no effects on joint stiffness. n = 8 in each group. **p < 0.01
compared to the control group
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acclimate to laboratory environment for one week prior to
the beginning of the experiment. All experiments were
performed in accordance with protocols approved by
Animal Care and Use Committee of the Fourth
Military Medical University.
CFA injection and NB001 administration
To induce arthritic pain of knee joint, CFA (10 μL, in 50 %
saline) was injected into the left knee joint cavity of mice
using a 30-gauge 1⁄2-in. needle every 7 days (on day 0, 7,
14, and 21) under isoflurane anesthesia [43]. For the ankle
joint pain model, 10 μL CFA was injected into the left hind
metatarsal footpad of mice on day 0. The same volume
saline was injected into the left knee joint cavity or hind
metatarsal footpad of the control mice. For the treatment,
NB001 (3 mg/kg, in saline) was administrated intraperito-
neally once a day from day 24 to day 28 for knee joint pain
models or from day 14 to day 18 for ankle joint pain
models. The first administration of NB001 was performed
after the behavioral tests on day 14 or day 24. At the third
and last administration of NB001, the behavioral tests were
completed within 2.5 h after NB001 administration. The
control and model (CFA) groups received intraperitoneal
injection of saline at the same time point.
Assessment of paw and knee joint edema
To quantify the effects of NB001 on the joint inflamma-
tion, the diameters across the ankle or knee joints were
assessed using a vernier caliper before and after CFA
injection at the different time points.
Behavioral measurements of arthritic joint pain
All behavioral tests were performed during the day time
and the animals were allowed to habituate to the labora-
tory room for at least 30 min before the tests. In all cases,
behavioral analysis was performed by a trained observer
blind to the experimental groups.
Evaluation of spontaneous pain and stimulus-evoked pain
Spontaneous pain and stimulus-evoked pain are two be-
havioral phenotype of arthritic joint pain and always used
as the measurements of arthritis [44]. They reflect the
clinical conditions of arthritic patients with joint pain at
rest and after joint movement respectively [6, 37]. Hind-
paw flinch is one indicator of spontaneous pain. Flinches
were calculated as the number of times mice raised its
hindpaw [44]. For the detection of flinching behavior, mice
were placed in cylindric plexiglas chambers with the
height of 30 cm and inside diameter of 20 cm for 30 min
acclimation. The numbers of spontaneous flinch were
recorded during 2 min. For the assessment of stimulus-
evoked pain, the use of normal limb was detected and
scored from 5 to 0 during spontaneous movement as previ-
ously reported [38, 39], 5 = normal use, 4 = partial limp, but
not pronounced, 3 = pronounced limp, 2 = limp and guard-
ing behavior, 1 = partial nonuse of limb in locomotor activ-
ity, 0 = totally lack of limb use. In addition, the limb-use
was detected under forced ambulation condition. The mice
were placed on a rotarod (Ji Liang Company, Shanghai,
China) at a speed of 17 rounds/min for 5 min. Limb-use
was scored: 4 = normal; 3 = limping; 2 = partial non-use of
left hind limb; 1 = substantial non-use of left hind limb; 0 =
non-use of left hind limb.
Mechanical allodynia test
Mice were put in individual plexiglas cages with a metal
mesh floor to acclimate environment for 30 min before
testing. Mechanical allodynia was detected with a set of
von Frey filaments (Stoelting) and evaluated by hind-
paw responsiveness to different stimulation. Mechanical
pressure from the 1.65 filament (force, 0.008 g) was
used to characterize the threshold stimulus based on
the up-down strategy. The filaments were applied ver-
tically to the dorsal surface of the hindpaw with suffi-
cient force to cause slight bending for 6 s.
Mechanical allodynia was detected five times with an
interval of 10 min within stimulation. Positive re-
sponses include licking, biting, flinching, and brisk
withdrawal of the hindpaw.
Thermal hyperalgesia test
Animals were placed in individual round container
and allowed to adapt for 30 min before the experi-
ment. Thermal hyperalgesia was evaluated by measur-
ing the latency of paw withdrawal (PWL) in response to a
radiant heat source [45] using a commercially available
plantar analgesia instrument (BME410A, Institute of
Biological Medicine, Academy of Medical Science, China).
The heat source was turned off when the mice lifted the
foot and the time from beginning to the ending of heat
application was defined as the PWL. In order to prevent
tissue damage resulted from long-time heat application,
the heat source would be cut off automatically at 20 s even
the mice did not lift the foot. The apparatus was modu-
lated to give a paw withdrawal latency of approximately
10 s in naïve mice. Left paws were tested at 5 min intervals
for a total of five trials. The mean PWL was obtained from
the latter three stimuli [46].
Assessment of joint hyperalgesia
The joint hyperalgesia was measured according to the
previous method [47] with little modification. Bending
and extension (one after the other with a 5 s interval
and five times in each direction) were applied to the
ankle or knee joint within its limits of range of motion.
The numbers of mice vocalized during each stimulus
(the bending and extension) were recorded, and score 0
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(no vocalization) or 1 (vocalization) was given depended
on the results. Thus, for each mouse the vocalization
score ranged from 0 to 10 at each joint [27, 48].
Measurement of joint stiffness
The joint stiffness scoring was examined according to
the previously reported method [32]. The mice were
held stably, then the ankle or knee joint was bended and
extended (once in each direction). The scores were given
according to the following standard: score 2, there were
restrictions of full range of joint movement in both
bending and extension; score 1, there was restriction of
movement of the joint only in one direction (bending or
extension); score 0, there was no restriction in both
direction [32].
Histopathologic analysis
On the last experimental day, animals were anesthe-
tized and sacrificed (day 28 after initial CFA injection
into knee joint or day 18 after initial CFA injection
into ankle joint) and the ipsilateral knee joints or
ankle joints were collected. For collecting knee joints,
the legs were cut through both the femur and the
tibia. Then the specimens were immerged into 10 %
neutral formalin to be post-fixed for 48 h. Subse-
quently, the fixed tissue was moved into decalcifying
solution (4 M formic acid) for 35 days to make the
bone completely demineralization. During this period,
the decalcifying solution was changed once a week.
The specimens were embedded in paraffin wax and
cut into 5 μm thick sections, and stained with
hematoxylin and eosin for microscopic assessment.
Experimental procedure
The experimental procedure was summarized in Fig. 7.
The upper one was experimental time course of ankle arth-
ritis model and the lower one was that of knee arthritis
model. All behavioral tests were performed prior to CFA
injection and on day 3, 7, 14, 16, 18 for ankle arthritis or
on day 4, 11, 17, 24, 26, 28 for knee arthritis after initial
CFA injection. The first administration of NB001 was given
after behavioral tests on day 14 for ankle joint arthritis
models or on day 24 for knee joint arthritis models. During
the treatment period, if there were behavioral measure-
ments, they were finished within 2.5 h after NB001 or sa-
line administration except it was specially mentioned.
Data analysis
Data were presented as the mean and standard errors of
the means (SEM). Statistical analysis of differences be-
tween two groups was performed by independent sam-
ple, two-tailed t test. Data of multiple groups were
evaluated using one-way analysis of variance (ANOVA)
for post hoc comparisons (SPSS 13.0). Data that passed
the homogeneity test were analyzed by the one-way
ANOVA least significant difference (LSD) test. Data that
did not pass the homogeneity test were analyzed by the
one-way ANOVA Dunnett’s test. In all cases, p < 0.05
was considered statistically significant.
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